BIND Therapeutics Inc (BIND)

0.14
0.01 3.33
OTC : Health Care
Prev Close 0.15
Open 0.15
Day Low/High 0.14 / 0.16
52 Wk Low/High 0.00 / 0.00
Volume 562.16K
Avg Volume 1.20M
Exchange OTC
Shares Outstanding 20.89M
Market Cap 16.29M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
BIND Therapeutics To Present At Cowen 34th Annual Healthcare Conference

BIND Therapeutics To Present At Cowen 34th Annual Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

3 Biotech Stocks Rising on Big Volume

3 Biotech Stocks Rising on Big Volume

Keep these biotech stocks trading on unusual volume on your radar.

BIND Therapeutics To Present At February Healthcare Conferences

BIND Therapeutics To Present At February Healthcare Conferences

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

BIND Therapeutics Announces Departure Of Chief Medical Officer

BIND Therapeutics Announces Departure Of Chief Medical Officer

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today announced that Greg Berk, M.

BIND Therapeutics To Be Added To Russell Indexes On December 20, 2013

BIND Therapeutics To Be Added To Russell Indexes On December 20, 2013

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that it will be added as a member of the...

4 Stocks Spiking on Big Volume

4 Stocks Spiking on Big Volume

Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

BIND Therapeutics And Amgen Amend Collaboration Agreement For Kinase Inhibitor Nanomedicine

BIND Therapeutics And Amgen Amend Collaboration Agreement For Kinase Inhibitor Nanomedicine

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins ™, announced today that it has amended its development and...

BIND Therapeutics Co-Founders Demonstrate Ability To Cross Biological Barriers With Targeted Therapeutic Nanoparticles

BIND Therapeutics Co-Founders Demonstrate Ability To Cross Biological Barriers With Targeted Therapeutic Nanoparticles

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that the company’s co-founders have...

RSI Alert: Bind Therapeutics (BIND) Now Oversold

RSI Alert: Bind Therapeutics (BIND) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

BIND Therapeutics Reports Third Quarter 2013 Financial Results

BIND Therapeutics Reports Third Quarter 2013 Financial Results

BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, today reported financial results for the three-month period...

BIND Therapeutics To Present At The Credit Suisse 2013 Healthcare Conference

BIND Therapeutics To Present At The Credit Suisse 2013 Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that Scott Minick, BIND’s President and...

BIND Awarded The RUSNANOPRIZE 2013 For Innovative Development Of Nanomedicine

BIND Awarded The RUSNANOPRIZE 2013 For Innovative Development Of Nanomedicine

BIND Therapeutics Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that BIND has been awarded the RUSNANOPRIZE 2013 for ...

BIND Therapeutics To Report Third Quarter 2013 Financial Results And Business Developments On November 5, 2013

BIND Therapeutics To Report Third Quarter 2013 Financial Results And Business Developments On November 5, 2013

BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM, announced today that it will report financial results for the...

Top Insider Trades: GEVA, ACW, BIND, WFT

Top Insider Trades: GEVA, ACW, BIND, WFT

The top 10 open-market insider purchases and sales filed at the SEC Friday.

BIND Therapeutics Announces Closing Of Initial Public Offering

BIND Therapeutics Announces Closing Of Initial Public Offering

BIND Therapeutics, Inc. (NASDAQ: BIND) announced today the closing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.

BioTech IPOs With Big Partners

BioTech IPOs With Big Partners

These biotech IPOs all have collaborations with big name companies says Equities.com Francis Gaskins.